Targeting syk kinase for the treatment of B-cell lymphoma
Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Ronald Levy(Hôpital Necker-Enfants Malades), Jonathan M. Irish(Vanderbilt University), Greg Coffey(Stanford University), Debra K. Czerwinski(Stanford University), Y Hitoshi(Stanford University)
Cited by 4
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k